<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578055</url>
  </required_header>
  <id_info>
    <org_study_id>BULQ-LC trial</org_study_id>
    <nct_id>NCT03578055</nct_id>
  </id_info>
  <brief_title>BDD With UDCA Therapy After Laparoscopic Cholecystectomy</brief_title>
  <acronym>BULQ-LC</acronym>
  <official_title>Prospective Study for the Effects of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycolic Acid Therapy on Liver Function and Quality of Life After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University Mokdong Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Study for the Effects of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycolic Acid
      Therapy on Liver Function and Quality of Life After Laparoscopic Cholecystectomy

      Primary endpoint: peak level of postoperative AST (aspartate transaminase) and postoperative
      ALT (alanine tansaminase)

      Secondary endpoint: postoperative GIQLI (Gastrointestinal Quality of Life index) score
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because the gallbladder is adjacent to the liver, liver enzymes are often elevated when
      cholecystitis occurs. BDD and UDCA drugs are known to be effective in preserving liver
      function. The use of BDD and UDCA drugs in patients with cholecystitis is expected to inhibit
      elevated liver enzyme levels and to maintain liver function. The aim of this study is to
      analyze the effects of BDD and UDCA medication on postoperative changes in hepatic enzyme
      levels and quality of life in patients LFT elevated cholecystitis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Aspartate Aminotransferase</measure>
    <time_frame>Postoperative 30 days</time_frame>
    <description>Serum aspartate aminotransferase level (U/ml) (continuous variable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Alanine Aminotransferase</measure>
    <time_frame>Postoperative 30 days</time_frame>
    <description>Serum Alanine Aminotransferase level (U/ml) (continuous variable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GIQLI (Gastrointestinal Quality of Life Index)</measure>
    <time_frame>Postoperative 30 days</time_frame>
    <description>Score of Quastionare for postoperative quality of life by GIQLI (Range, 0 - 180)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Cholecystitis, Acute</condition>
  <condition>Cholecystitis, Chronic</condition>
  <arm_group>
    <arm_group_label>BDD with UDCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperative BDD with UDCA treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDD with UDCA</intervention_name>
    <description>Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery</description>
    <arm_group_label>BDD with UDCA</arm_group_label>
    <other_name>UDEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No UDEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for surgery due to chronic cholecystitis and acute cholecystitis

        Exclusion Criteria:

          -  Failure to obtain consent

          -  Under 19 years

          -  If you have intellectual ability to understand this study

          -  When performing cholecystectomy with other operations

          -  Total bilirubin levels&gt; 2 mg / dl

          -  If you are enrolled in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huisong Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huisong Lee, M.D., Ph.D.</last_name>
    <phone>+82-2-2650-5694</phone>
    <email>huisong.lee@ewha.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huisong Lee, M.D., Ph.D.</last_name>
      <phone>+82-2-2650-5694</phone>
      <email>huisong.lee@ewha.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University Mokdong Hospital</investigator_affiliation>
    <investigator_full_name>Huisong Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

